Chauhan Sonali, Shrivastava Deepti, Dhande Rajasbala, Deo Asawari
Department of Obstetrics and Gynaecology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science (Deemed to be University), Wardha, IND.
Department of Radiology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science (Deemed to be University), Wardha, IND.
Cureus. 2022 Sep 7;14(9):e28909. doi: 10.7759/cureus.28909. eCollection 2022 Sep.
Ovarian cancers are one of the most common gynecological cancers and serous tumor is one of the most common histological form of extrauterine female genital tract tumors. While ovarian serous carcinoma is a well-studied human gynecologic malignancy, this high-grade tumor remains lethal.
A 50-year-old female with P2L2A2 (Para-2, Live-2, Abortion-2) presented with pain in the abdomen for six months. Investigations were done, which revealed bilateral large ovarian cystic lesion suggestive of ovarian malignancy. She underwent six cycles of chemotherapy followed by exploratory laparotomy.
We examined the precipitating factors, laboratory abnormalities including cancer antigen 125 (CA-125) levels, treatment strategies including neoadjuvant therapy and debulking surgery, and clinical recovery in ovarian malignancy.
Primary debulking surgery (PDS), although the preferred treatment for ovarian cancer, is accompanied by combination chemotherapy based on platinum. However, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) has gained a reputation as a legitimate therapeutic technique specifically for patients with stage IV unresectable bulky tumors or poor general condition. Treatment with NACT is now expected to become a routine treatment or a successful treatment choice for advanced epithelial ovarian cancer (EOC).
卵巢癌是最常见的妇科癌症之一，浆液性肿瘤是女性生殖道宫外肿瘤最常见的组织学类型之一。虽然卵巢浆液性癌是一种研究充分的人类妇科恶性肿瘤，但这种高级别肿瘤仍然具有致命性。
一名50岁女性，孕2产2流产2次（P2L2A2），出现腹痛6个月。进行了相关检查，发现双侧卵巢巨大囊性病变，提示卵巢恶性肿瘤。她接受了六个周期的化疗，随后进行了剖腹探查术。
我们研究了卵巢恶性肿瘤的诱发因素、包括癌抗原125（CA-125）水平在内的实验室异常、包括新辅助治疗和肿瘤减灭术在内的治疗策略以及临床恢复情况。
原发性肿瘤减灭术（PDS）虽然是卵巢癌的首选治疗方法，但需联合基于铂类的化疗。然而，新辅助化疗（NACT）后行间隔肿瘤减灭术（IDS）已成为一种合理的治疗技术，尤其适用于IV期不可切除的大块肿瘤或全身状况较差的患者。目前，NACT治疗有望成为晚期上皮性卵巢癌（EOC）的常规治疗或成功的治疗选择。
